Summary & Overview
HCPCS C9782: Transcatheter Intramyocardial Autologous Bone Marrow Transplantation
HCPCS Level II code C9782 designates a complex, blinded investigational procedure for select patients with symptomatic heart failure or refractory angina. The code encompasses transcatheter intramyocardial transplantation of autologous bone marrow cells (or placebo), autologous bone marrow harvest and preparation, left heart catheterization with ventriculography, and all associated laboratory and imaging services. This code is relevant nationally as it captures bundled investigational cardiac interventions performed under an approved Investigational Device Exemption (IDE) study and affects claims processing, coverage determinations, and study reimbursement reporting.
Key payers included in this overview are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise summary of the clinical context of the procedure, the service setting, and what the code represents for billing and study documentation. The publication provides benchmarks and policy-relevant context for coverage and reimbursement considerations, flags common modifiers reported with this code, and explains the procedural components bundled under C9782. The content is intended for national audiences including billing professionals, clinical research administrators, and health policy analysts.
Data not available in the input: specific associated taxonomies, ICD-10 diagnoses, related codes, payer-specific coverage rules, and service line details.
Billing Code Overview
HCPCS Level II code C9782 describes a blinded investigational procedure for patients with New York Heart Association (NYHA) Class II or III heart failure, or Canadian Cardiovascular Society (CCS) Class III or IV chronic refractory angina. The service includes transcatheter intramyocardial transplantation of autologous bone marrow cells (e.g., mononuclear) or placebo control, autologous bone marrow harvesting and preparation for transplantation, left heart catheterization including ventriculography, and all laboratory services and imaging with or without guidance (for example, transthoracic echocardiography, ultrasound, fluoroscopy).
Service type: Investigational transcatheter intramyocardial cellular transplantation with associated harvest, catheterization, imaging, and laboratory services.
Typical site of service: Hospital-based interventional cardiology or catheterization laboratory with associated inpatient or outpatient procedural and imaging support.
Clinical & Coding Specifications
Clinical Context
A 62-year-old male with ischemic cardiomyopathy (NYHA Class III) and chronic refractory angina (CCS Class III) enrolled in an FDA-approved investigational device exemption (IDE) randomized, blinded trial comparing transcatheter intramyocardial transplantation of autologous bone marrow mononuclear cells versus placebo. Pre-procedure evaluation includes history and physical, informed consent for study and investigational therapy, complete blood count and metabolic panel, transthoracic echocardiography, coronary angiography review, and assessment for bone marrow harvest suitability. On the day of service, the patient undergoes autologous bone marrow aspiration in the interventional suite, on-site cell preparation, left heart catheterization with ventriculography and transcatheter intramyocardial injection under fluoroscopic and echocardiographic guidance. All laboratory testing (pre-, intra-, post-procedure) and imaging are performed per protocol. Post-procedure monitoring occurs in a cardiac observation or inpatient unit with serial vitals, cardiac enzymes, and imaging as required by the investigational protocol. Typical payors include Medicare, Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and other commercial carriers; billing uses HCPCS Level II code C9782 to capture the bundled investigational study procedure.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/Unspecified modifier |